Longevity Startups
430 companies tagged Longevity, with their investors and founders.
EdenRoc Sciences is a life sciences holding company that founds and funds subsidiary biotechnology companies addressing diseases of aging, with assets spanning genomic detection, clinical-stage pharmaceuticals, forensics, and biologic-based consumer products. Its subsidiaries operate autonomously while sharing board oversight and centralized business functions, and its work spans diagnostics and therapeutics across biotech and healthcare markets.
0 investors
FibroBiologics develops fibroblast cell-based therapies for chronic and degenerative conditions, targeting areas such as multiple sclerosis and other autoimmune diseases, degenerative disc disease, wound healing, and age-related organ decline (thymus and spleen). The company is a clinical-stage biotech positioning fibroblasts as an alternative to stem cells for regeneration and immune modulation.
0 investors
Foment Bio develops non-viral, off-the-shelf plasmid gene therapy constructs that trigger in vivo production of regenerative exosomes to restore tissue microvasculature, resolve inflammation, and prevent cell death. The therapy targets age-related and cardiometabolic chronic diseases including heart failure, chronic kidney disease, erectile dysfunction, and wound healing, and has advanced into FDA clinical trials.
0 investors
Fountain is a biotech company developing first-in-class therapies for diseases and conditions caused by aging, using in vitro and in vivo screening platforms to identify drug candidates. Its lead programs include a topically applied small-molecule combination to reverse age- and weight-loss-associated skin atrophy and a small-molecule modulator to preserve lean tissue and muscle mass in sarcopenia and GLP agonist-induced atrophy.
0 investors
Generian Pharmaceuticals is a preclinical biotechnology company developing orally available small molecule therapeutics for diseases with high unmet need, particularly conditions currently treated by biologics. It targets age-related diseases including metabolic disorders, neurodegeneration, and inflammation.
0 investors
Gracewell operates two boutique residential care homes offering assisted living for seniors, with a focus on small-scale, home-like settings and personalized wellness support. The homes are designed as an alternative to large facilities, emphasizing intimate care relationships for residents and their families.
0 investors
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics as first-in-class immunotherapies for autoimmune diseases, cancer, and senescence-associated dysplasia. It uses proprietary drug discovery platforms to create multi-specific cytokines, targeted immune checkpoint inhibitors, and immune-cell engagers, with lead candidates in commercial and clinical stages.
0 investors
Human Continuum develops platelet-derived exosome products, including a cell-free biologic, injectable hydrogel-exosome therapies for orthopedic conditions, point-of-care diagnostics, and topical skincare formulations for skin repair and anti-aging. Its offerings target the longevity, orthopedics, dermatology, and med-spa markets.
0 investors
iBio discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies against hard-to-drug targets. The company operates in the biotech and drug discovery space.
0 investors
Immunaeon offers personal cryogenic banking of an individual's own immune cells, collecting and storing healthy cells for potential future cell-based treatments. It provides clinician-led consultations on storage and diagnosis-related decisions for individuals and families planning ahead of illness.
0 investors
InGeneron develops regenerative cell therapies that use a patient's adult stem cells and other regenerative cells harvested from fat or bone marrow to treat specific injuries. The company focuses on developing FDA-approved therapies through clinical trials and research in the regenerative medicine field.
0 investors
Intervene Immune develops treatments aimed at rejuvenating the immune system by regenerating the thymus and reversing biological aging, building on its TRIIM and TRIIM-X clinical trials. The company applies aging biology and epigenetic age measurement to human longevity interventions.
0 investors
The page presents team members affiliated with Cambrian Bio, describing roles in R&D project management, business operations, and medicinal chemistry consulting within drug discovery and development. The individuals have backgrounds in developing medicines and small-molecule therapeutics across pharma and biotech.
0 investors
Jupiter Biomedical Research develops two drug candidates: JBR-102, a new chemical entity in preclinical studies for glioblastoma and other solid tumor and hematologic cancers, and JBR-201, an antiviral therapeutic tested against measles, herpes, and other viruses. The company focuses on commercializing these oncology and antiviral treatments.
0 investors
Jyzen offers personalized integrative medicine and wellness programs focused on healthy aging, longevity, chronic disease resolution, cognitive function, and performance optimization. It combines medical providers with fitness and wellness practitioners, using a diagnostics, detox, optimization, and maintenance process to deliver individualized care.
0 investors
Khloris Biosciences develops iPSC-based cancer vaccines, using induced pluripotent stem cells to trigger a multi-faceted anti-tumor immune response. The company focuses on identifying novel targets and vaccine candidates for cancer treatment.
0 investors
Klothea develops mRNA-based therapeutics designed to trigger adjustable and reversible secretion of the Klotho protein, aiming to address the protein deficit linked to age-related diseases. The company uses proprietary mRNA and safe nanocarriers intended for repeated use, and is also evaluating delivery methods such as extracellular vesicles (exosomes).
0 investors
Koyo Sciences is a biotechnology company developing an oral human growth hormone therapy derived from algae as a non-invasive alternative to injectable treatments for Growth Hormone Deficiency. Its research spans biology, chemistry, and data with a focus on health and sustainability.
0 investors
Longevity Medical Institute is a 15,000 sq. ft. medical center offering stem cell therapy, regenerative medicine, and longevity treatments, supported by an on-site stem cell biotechnology lab, clinical lab, AI-enhanced full-body MRI, and a surgical center. Located in San José del Cabo (Los Cabos), Mexico, it serves patients seeking proactive care for aging, recovery, and long-term health under federal COFEPRIS licensure.
0 investors
MD Hyperbaric operates physician-led clinics offering Hyperbaric Oxygen Therapy (HBOT) using FDA-cleared hard-shell chambers, treating patients for conditions such as post-surgical recovery, brain injury, athletic recovery, chronic inflammation, and post-COVID symptoms. Sessions are protocol-driven and overseen by licensed medical providers, offered on an out-of-pocket basis at local treatment centers.
0 investors
Metallomix is a drug development company working on isotope-selective modulators using non-radioactive stable isotopes (currently zinc-64) to target inflammation and oxidative stress. It develops treatments for oncological, metabolic, neurological, and autoimmune conditions through its ISM (isotope-selective modulation) platform, with ongoing and planned clinical trials.</parameter> <parameter name="founders">[{"full_name": "Max Temnik", "title": "Founder"}]
0 investors
MitoSense develops Mitochondria Organelle Transplantation (MOT) technology, a cellular biotherapy that uses mitochondria to treat neurodegenerative diseases such as ALS, Parkinson's, and Alzheimer's. The company holds an exclusive license to the MOT technology and is developing it as a cell therapy.
0 investors
Myosana Therapeutics develops non-viral, muscle-targeted gene therapies aimed at slowing skeletal muscle degeneration and heart failure in Duchenne muscular dystrophy (DMD) and other neuromuscular and cardiac diseases. The company works in the biotech and gene therapy field.
0 investors
Natsar Pharmaceuticals is an applied research and drug development company developing RK-33, a first-in-class small molecule inhibitor of the DDX3 RNA helicase for treating cancers such as lung, breast, prostate, sarcoma, and pancreatic tumors, as well as viral infections including SARS-CoV-2 and HIV. The company is preparing to file an IND and move RK-33 into Phase 1 clinical trials.
0 investors